• 33 million euros from National Growth Fund for RegMed XB Pilot factory for regenerative medicine
  • Home
  • News & Events
  • News
  • 33 million euros from National Growth Fund for RegMed XB Pilot factory for regenerative medicine
PUBLISHED
14 Apr 2022

SHARE THIS

33 million euros from National Growth Fund for RegMed XB Pilot factory for regenerative medicine

promising therapies for patients one step closer

The urgency is high in the field of regenerative medicine. Promising therapies are in the pipeline from the lab to the patient, but a good infrastructure is needed to make this possible. With that promise and funding from the national growth fund, RegMed XB started building a pilot plant for regenerative medicine. The first grant of 23 million euros was mainly intended for physical infrastructure and the second part of a maximum of 33 million is also intended for further development and upscaling. Today, the government decided to definitively grant the second phase as well. The realization of the pilot plant not only contributes to affordable healthcare. It is also an important means to increase the innovative power of the Netherlands.

Bernard Mulder (CEO of RegMed XB): "We are pleased that the good progress on the realization of the infrastructure of this Pilot Factory has led to this positive decision by the government. This will allow us to build the infrastructure needed for the development and production of regenerative therapies that can help patients in the future."

A unique cooperation
The new facilities in different regions together form the national pilot factory. They cover the entire chain of development and production of stem cells, mini-organs, tissues and smart (bio) materials.

  • Leiden: since mid-2021, the renovation and furnishing of the infrastructure has started. Leiden realizes this in the Dutch Center for the Clinical Advancement of Stem cell and Gene Therapies (NecstGen). In addition, the Leiden University Medical Center is working on a facility where induced pluripotent stem cells and their applications can be developed. The facility is expected to be completed in the summer of 2022.
  • Brabant: the Smart Biomaterials Consortium Foundation (SBMC) has started the realization of a high-quality infrastructure as the basis of a production ecosystem for bio- and biocompatible materials suitable for regenerative medicine applications.
  • Utrecht: the UMC Utrecht realizes the Innovation Center for Advanced Therapies with a facility for bio-fabrication, a (GMP) simulation environment and a GMP production facility for regenerative medicine.
  • Limburg: ReGEN Biomedical, in collaboration with Maastricht University, has started designing and developing an infrastructure for the production line for (small) tissues.

Greater innovative power
The Netherlands is already one of the forerunners in the field of regenerative medicine. The pilot plant provides an important boost in this emerging industry. Thanks to the support of the National Growth Fund and the investment of provinces, private parties and knowledge institutions, the ecosystem is created in which parties work closely together and that brings a cure for chronic diseases a step closer.

RegMed XB
Regenerative Medicine Crossing Borders (RegMed XB) is a patient-driven public-private partnership dedicated to bringing affordable regenerative medicine solutions to patients with chronic conditions. Regenerative medicine focuses on repairing damage to cells, tissues and organs that can prevent or cure chronic diseases. For this purpose, stem cells, mini-organs, tissues and smart (bio) materials are used. RegMed XB connects top clusters in the field of regenerative medicine in different regions in the Netherlands (Leiden, Brabant, Utrecht and Limburg), and Flanders (Leuven). RegMed XB's ambitious research currently focuses on curing type 1 diabetes, kidney failure, osteoarthritis and cardiovascular disease.

Bernard Mulder, MD MBA
General Director

logo regmed xb

Have something to share?

Now you can contribute to keep our news section fresh and up-to date with relevant events and grants, research results and high impact publications related to REGMED XB’ Moonshots. Contributions can be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.. Please submit the text in English and include a short title. We are looking forward to your input!

  • Diabetes FondsDiabetes Fonds
  • Leids Universitair Medisch CentrumLeids Universitair Medisch Centrum
  • Provincie UtrechtProvincie Utrecht
  • RijksoverheidRijksoverheid
  • Health HollandHealth Holland
  • Maastricht UMC+Maastricht UMC+
  • Provincie LimburgProvincie Limburg
  • TU/eTU/e
  • NierstichtingNierstichting
  • Provincie Noord-BrabantProvincie Noord-Brabant
  • Universiteit LeidenUniversiteit Leiden
  • LeidenLeiden
  • Stichting DONStichting DON
  • ReumaNederlandReumaNederland
  • Maastricht UniversityMaastricht University
  • UMC UtrechtUMC Utrecht
  • Utrecht UniversityUtrecht University
  • KU LeuvenKU Leuven
  • VIBVIB
  • HartstichtingHartstichting
  • 300Microns300Microns
  • Access2boneAccess2bone
  • Chemelot InSciTeChemelot InSciTe
  • Cyto smartCyto smart
  • Dutch CardioVascular AllianceDutch CardioVascular Alliance
  • Flanders State of the ArtFlanders State of the Art
  • FUJIFILMFUJIFILM
  • GalápagosGalápagos
  • HCM MedicalHCM Medical
  • Kuros BiosciencesKuros Biosciences
  • LifeTec GroupLifeTec Group
  • MateriomicsMateriomics
  • MimetasMimetas
  • Ministerie van Economische Zaken en KlimaatMinisterie van Economische Zaken en Klimaat
  • Ministerie van Onderwijs Cultuur en WetenschapMinisterie van Onderwijs Cultuur en Wetenschap
  • Ministerie van Volksgezondheid, Welzijn en SportMinisterie van Volksgezondheid, Welzijn en Sport
  • NcardiaNcardia
  • Nestegg BiotechNestegg Biotech
  • NTrans TechnologiesNTrans Technologies
  • Ostheo PharmaOstheo Pharma
  • Provincie Zuid-HollandProvincie Zuid-Holland
  • ScinusScinus
  • Starfish InnovationsStarfish Innovations
  • StentitStentit
  • SupraPolixSupraPolix
  • veldlaserveldlaser
  • VisualsonicsVisualsonics
  • XeltisXeltis

Information for

Contact information

  • Stichting REGMED XB
  • Minderbroedersberg 4-6, 6211 LK  Maastricht
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Connect with us

Copyright © 2021 RegMed XB. All rights reserved
Realisation & design by Joomlapartner